Proteome Sciences, a provider in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development, has entered into a PS Biomarker Services contract with Eisai.

PS Biomarker Services will provide measurement of candidate biomarkers for Alzheimer’s disease using its AD-TMT-SRM assay set on human sample material.

Proteome Sciences chief executive Christopher Pearce said they are delighted to add Eisai to the growing list of PS Biomarker Services clients.

"As a global pharmaceutical company, Eisai has the opportunity to select from many contract service organisations and they have recognised the advantages of using our mass spectrometric assay capabilities, acknowledging our strong track record of delivery in biomarker discovery and validation, as well as rapid MS assay development," Pearce said.